Related Experiment Videos
Rifampicin-induced lupus erythematosus
1Department of Dermatology, University Hospital of Wales, Cardiff, Wales, UK. patelgk@cardiff.ac.uk
Clinical and Experimental Dermatology
|June 26, 2001
Summary
Rifampicin rarely causes lupus erythematosus (LE), but combination therapy may increase risk. This case highlights florid cutaneous features as a diagnostic clue for drug-induced LE.
Area of Science:
- Rheumatology
- Pharmacology
- Dermatology
Background:
- Rifampicin is a widely used antibiotic with a low reported incidence of inducing lupus erythematosus (LE).
- Drug-induced LE can present differently from systemic LE, with cutaneous manifestations being a key diagnostic indicator.
Observation:
- A case of rifampicin-induced LE is presented.
- The patient exhibited prominent and severe skin symptoms.
Findings:
- Rifampicin-induced LE is infrequently reported, with only four prior cases.
- Concurrent use of clarithromycin or ciprofloxacin, which share cytochrome P450 metabolism with rifampicin, may elevate rifampicin blood levels and contribute to LE development.
- Cutaneous manifestations, though uncommon, are significant in diagnosing drug-induced LE.
Implications:
- This case underscores the importance of considering rifampicin-induced LE, especially when patients present with unusual cutaneous features.
- Awareness of potential drug interactions affecting rifampicin metabolism is crucial for clinicians.
- Further investigation into the mechanisms and risk factors for rifampicin-induced LE is warranted.